World affairs & perspectives
Sign inJoin us
← Latest news

From South China Morning Post

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over...

Read the full report at South China Morning Post ↗